Precision BioSciences appoints Michael Amoroso as President and CEO, effective Oct 15, 2021

PRECISION BIOSCIENCES INC

Amoroso succeeds co-founder Matt Kane, who transitions to advisor through Oct 2022.
Annual base salary $600k; target bonus 60% of base plus $200k one-time payment in 2021.
Inducement grants: option to buy 850k shares (4-yr vest, 25% year 1) and RSUs with $237k grant-date fair value (1-yr cliff).
Additional option for 250k shares to be granted on first anniversary of effective date, vests over 4 years.
Relocation assistance up to $50k (grossed up) and attorney fees up to $10k.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mathew Kane

President and Chief Executive Officer

DTIL · PRECISION BIOSCIENCES INC

Effective: 2021-10-15
Successor: Michael Amoroso
Filed: September 27, 2021, 7:59 PM ET

Mr. Amoroso succeeds Mathew Kane who, as previously reported, agreed to cease serving in both capacities effective with his successor’s commencement of service with the Company and to serve as a non-employee advisor to the Company through October 1, 2022

Appointed

Michael Amoroso

Director

DTIL · PRECISION BIOSCIENCES INC

Effective: 2021-10-15
Filed: September 27, 2021, 7:59 PM ET

appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021

Appointed

Michael Amoroso

President and Chief Executive Officer

DTIL · PRECISION BIOSCIENCES INC

Effective: 2021-10-15
Filed: September 27, 2021, 7:59 PM ET

appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mathew Kane departed as President and Chief Executive Officer at PRECISION BIOSCIENCES INC.

Action: agreed to cease serving
Role: President and Chief Executive Officer

Exact text from the filing

Mr. Amoroso succeeds Mathew Kane who, as previously reported, agreed to cease serving in both capacities effective with his successor’s commencement of service with the Company and to serve as a non-employee advisor to the Company through October 1, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Amoroso was appointed as Director at PRECISION BIOSCIENCES INC.

Action: appointed
Role: Director

Exact text from the filing

appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Amoroso was appointed as President and Chief Executive Officer at PRECISION BIOSCIENCES INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021

View on SEC.gov

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001564590-21-048960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.